GSK plc 6-K, filed Apr 16, 2024
GSK plc (GSK)
6-K
2024-04-16
For: 2024-04-16
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on April 16, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
The following amendment
has been made to the 'Director/PDMR Shareholding' announcement
released on 15 April 2024 under RNS No 6709K:
- A typographical correction to the share price for the
transaction shown in the table below.
All other details to the original announcement remain
unchanged.
The amended table is shown below.
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
|
a)
|
Name
|
David
Redfern
|
|||
|
b)
|
Position/status
|
Chief
Strategy Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Amendment
|
|||
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 11 April 2024, on Ordinary Shares held
within an ISA
|
|||
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.3860
|
19
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated volume
Price
|
|
||||
|
e)
|
Date of
the transaction
|
2024-04-12
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
16, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|